Recombinant Anti-SMAD4 Antibody [SMAD/6309R] (A278027)

Anti-SMAD4 Antibody [SMAD/6309R]

Recombinant rabbit monoclonal [SMAD/6309R] antibody to SMAD4.

Signaling from the ligand-activated membrane receptor serine/threonine kinases to nuclear targets is mediated by a set of evolutionarily conserved proteins known as DPC4. Upon ligand binding, the receptors of the TGF-β family phosphorylate SMAD proteins (SMAD1 and SMAD2). These proteins then move into the nucleus, where they activate transcription. To carry out this function, the receptor activated SMAD1 and 2 require association with the product of deleted in pancreatic carcinoma, locus 4 (DPC4), also known as SMAD4. SMAD4/DPC4 is also implicated as a tumor suppressor, since it is inactivated in more than half of pancreatic carcinomas and to a lesser extent in a variety of other cancers. The lack of SMAD4 expression is present in approximately 80% of cases of pancreatic adenocarcinoma, but rarely in endometrial (0%), colorectal (0%), ovarian (3%), lung (0%), breast (2%) adenocarcinomas, and malignant melanoma (4%). SMAD4is an important marker for confirming a diagnosis of pancreatic adenocarcinoma.

IHC-P: 1-2 µg/ml

Human, Mouse, Rat

Recombinant full-length human SMAD4 protein.

Rabbit

Monoclonal

SMAD/6309R

IgG

Protein A/G chromatography.

200 µg/ml

61 kDa

Liquid

Supplied in 10mM Phosphate Buffered Saline with 0.05% BSA and 0.05% Sodium Azide.

Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.

This monoclonal antibody is also available in a different formulation without BSA and Sodium Azide - Anti-SMAD4 Antibody [SMAD/6309R] - BSA and Azide free (A278615).

Deletion target in pancreatic carcinoma 4, DPC4, hSMAD4, MAD homolog 4, MADH4, Mothers against decapentaplegic homolog 4, Mothers against DPP homolog 4, SMAD 4, SMAD family member 4